Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Encéphale 2020-06, Vol.46 (3S), p.S126
Hauptverfasser:	Bouaziz, N, Ben Rejeb, H, Ateb, S, Fourati, T, Chammas, F, Baha, D, Rosetti, R, Kalalou, K, Saba, G, Benadhira, R, Januel, D
Format:	Artikel
Sprache:	fre
Schlagworte:	Anticonvulsants - administration & dosage Anticonvulsants - therapeutic use Antipsychotic Agents - administration & dosage Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Betacoronavirus Clozapine - administration & dosage Clozapine - adverse effects Clozapine - therapeutic use Coronavirus Infections - complications COVID-19 Delayed-Action Preparations Drug Resistance Drug Therapy, Combination Humans Immunologic Factors - administration & dosage Immunologic Factors - adverse effects Immunologic Factors - therapeutic use Lithium Carbonate - administration & dosage Lithium Carbonate - therapeutic use Male Middle Aged Paliperidone Palmitate - administration & dosage Paliperidone Palmitate - therapeutic use Pandemics Pneumonia, Viral - complications Psychotic Disorders - drug therapy SARS-CoV-2 Sialorrhea - chemically induced Treatment Outcome Valproic Acid - administration & dosage Valproic Acid - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!